The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents beta-lactam antibiotic resistance, but with the same safe and effective mechanism of action of beta-lactams.

Proceeds will be used to advance the Venatorx Pharmaceuticals' portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections.